Infections in liver transplant recipients

World Journal of Hepatology

Volumn 3, Issue 4, 2011, Pages 83-92

  Romero, Fabian A ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aspergillosis; Bacteremia; Candidemia; Cytomegalovirus; Transplant

Indexed keywords

EID: 80054739953     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v3.i4.83     Document Type: Review

References (92)

1. Arnow PM. Infections following orthotopic liver transplantation. HPB Surg 1991; 3: 221-232; discussion 232-233
2. Moreno A, Cervera C, Gavaldá J, Rovira M, de la Cámara R, Jarque I, Montejo M, de la Torre-Cisneros J, Miguel Cisneros J, Fortún J, López-Medrano F, Gurguí M, Muñoz P, Ramos A, Carratalá J. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant 2007; 7: 2579-2586
3. Watt KD, Burak KW, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner E, Yoshida EM. Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. Can J Gastroenterol 2008; 22: 153-154
4. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality postliver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427
5. Bert F, Larroque B, Paugam-Burtz C, Janny S, Durand F, Dondero F, Valla DC, Belghiti J, Moreau R, Nicolas-Chanoine MH. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl 2010; 16: 393-401
6. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, Detre K, Wei Y, Everhart J. Long-term results and modeling to predict outcomes in recipients with HCV infecWJH tion: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120-1130
7. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, Karchmer AW. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-652
8. del Pozo JL. Update and actual trends on bacterial infections following liver transplantation. World J Gastroenterol 2008; 14: 4977-4983
9. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614
10. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703
11. Kim YJ, Kim SI, Wie SH, Kim YR, Hur JA, Choi JY, Yoon SK, Moon IS, Kim DG, Lee MD, Kang MW. Infectious complications in living-donor liver transplant recipients: a 9-year single-center experience. Transpl Infect Dis 2008; 10: 316-324
12. Linden PK. Approach to the immunocompromised host with infection in the intensive care unit. Infect Dis Clin North Am 2009; 23: 535-556
13. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, Pfaller M, Steinbach WJ, Webster KM, Marr KA. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: 220-229
14. Kawecki D, Chmura A, Pacholczyk M, Lagiewska B, Adadynski L, Wasiak D, Czerwinski J, Malkowski P, Sawicka-Grzelak A, Kot K, Wroblewska M, Rowinski W, Durlik M, Paczek L, Luczak M. Bacterial infections in the early period after liver transplantation: etiological agents and their susceptibility. Med Sci Monit 2009; 15: CR628-CR637
15. Moon DB, Lee SG. Liver transplantation. Gut Liver 2009; 3: 145-165
16. Tenza E, Bernardo CG, Escudero D, Otero J, Quindós B, Miyar A, Vázquez L, Taboada F, Rodríguez M, González-Dìéguez L, González-Pinto I, Barneo L. Liver transplantation complications in the intensive care unit and at 6 months. Trans-plant Proc 2009; 41: 1050-1053
17. Safdar N, Said A, Lucey MR, Knechtle SJ, D'Alessandro A, Musat A, Pirsch J, McDermott J, Kalayoglu M, Maki DG. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis 2004; 39: 517-525
18. Kim SI, Kim YJ, Jun YH, Wie SH, Kim YR, Choi JY, Yoon SK, Moon IS, Kim DG, Lee MD, Kang MW. Epidemiology and risk factors for bacteremia in 144 consecutive living-donor liver transplant recipients. Yonsei Med J 2009; 50: 112-121
19. Linares L, García-Goez JF, Cervera C, Almela M, Sanclemente G, Cofán F, Ricart MJ, Navasa M, Moreno A. Early bacteremia after solid organ transplantation. Transplant Proc 2009; 41: 2262-2264
20. Reid GE, Grim SA, Sankary H, Benedetti E, Oberholzer J, Clark NM. Early intra-abdominal infections associated with orthotopic liver transplantation. Transplantation 2009; 87: 1706-1711
21. Shi SH, Kong HS, Xu J, Zhang WJ, Jia CK, Wang WL, Shen Y, Zhang M, Zheng SS. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11: 405-412
22. Asensio A, Ramos A, Cuervas-Mons V, Cordero E, Sánchez-Turrión V, Blanes M, Cervera C, Gavalda J, Aguado JM, Torre-Cisneros J. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl 2008; 14: 799-805
23. Garzoni C. Multiply resistant gram-positive bacteria methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S41-S49
24. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolidresistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346: 867-869
25. Muñoz P. Multiply resistant gram-positive bacteria: vancomycin-resistant enterococcus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S50-S56
26. van Delden C, Blumberg EA. Multidrug resistant gramnegative bacteria in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S27-S34
27. Paterson DL, Singh N, Rihs JD, Squier C, Rihs BL, Muder RR. Control of an outbreak of infection due to extended-spectrum beta-lactamase--producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001; 33: 126-128
28. Bert F, Galdbart JO, Zarrouk V, Le Mée J, Durand F, Mentré F, Belghiti J, Lambert-Zechovsky N, Fantin B. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis 2000; 31: 1295-1299
29. Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl 2003; 9: 754-759
30. Russell DL, Flood A, Zaroda TE, Acosta C, Riley MM, Busuttil RW, Pegues DA. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008; 8: 1737-1743
31. Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, Marino IR. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000; 30: 322-327
32. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5: 751-762
33. Akin K, Ozturk A, Guvenc Z, Isiklar I, Haberal M. Localized fluid collections after liver transplantation. Transplant Proc 2006; 38: 627-630
34. Said A, Safdar N, Lucey MR, Knechtle SJ, D'Alessandro A, Musat A, Pirsch J, Kalayoglu M, Maki DG. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant 2004; 4: 574-582
35. Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9: 835-843
36. Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004; 10: 844-849
37. McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, Mackin ML, Kauffman CA. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006; 42: 195-203
38. Gearhart M, Martin J, Rudich S, Thomas M, Wetzel D, Solomkin J, Hanaway MJ, Aranda-Michel J, Weber F, Trumball L, Bass M, Zavala E, Steve Woodle E, Buell JF. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clin Transplant 2005; 19: 711-716
39. Mathers AJ, Cox HL, Bonatti H, Kitchel B, Brassinga AK, Wispelwey B, Sawyer RG, Pruett TL, Hazen KC, Patel JB, Sifri CD. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009; 11: 257-265
40. Levitsky J, Doucette K. Viral hepatitis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S116-S130
41. Ison MG, Green M. Adenovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S161-S165
42. Ison MG, Michaels MG. RNA respiratory viral infections in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S166-S172
43. Kumar D, Morris MI, Kotton CN, Fischer SA, Michaels MG, Allen U, Blumberg EA, Green M, Humar A, Ison MG. Guidance on novel influenza A/ H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10: 18-25
44. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S78-S86
45. Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S97-S100
46. Pergam SA, Limaye AP. Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S108-S115
47. Zuckerman R, Wald A. Herpes simplex virus infections in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S104-S107
48. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010; 50: 1439-1447
49. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20: 202-213
50. Boin ID, Boteon YL, Stucchi RS, Pereira MI, Portugal TC, Udo EY. Serological profile of pretransplantation liver patients. Transplant Proc 2010; 42: 491-493
51. Dahiya D, Lee CF, Chan KM, Wu TJ, Chou HS, Cheng SS, Lee WC. A short-term preemptive treatment for cytomegalovirus infection in seropositive patients after liver transplantation. J Hepatobiliary Pancreat Sci 2011; 18: 32-38
52. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10: 157-161
53. Koffron A, Stein JA. Liver transplantation: indications, pretransplant evaluation, surgery, and posttransplant complications. Med Clin North Am 2008; 92: 861-888, ix
54. van de Berg PJ, Heutinck KM, Raabe R, Minnee RC, Young SL, van Donselaar-van der Pant KA, Bemelman FJ, van Lier RA, ten Berge IJ. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis 2010; 202: 690-699
55. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 2004; 11: 77-86
56. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10: 60-65
57. Razonable RR, Paya CV. Infections and allograft rejection -intertwined complications of organ transplantation. Swiss Med Wkly 2005; 135: 571-573
58. Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on long-term transplant outcome. Curr Opin Organ Transplant 2010; 15: 492-498
59. Kim JM, Kim SJ, Joh JW, Kwon CH, Shin M, Kim EY, Moon JI, Jung GO, Choi GS, Lee SK. Early and delayed onset cytomegalovirus infection of liver transplant recipients in endemic areas. Transplant Proc 2010; 42: 884-889
60. Husain S, Pietrangeli CE, Zeevi A. Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 2009; 21: 1-9
61. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846
62. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461-1464
63. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965-981
64. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8: 2111-2118
65. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795
66. Singh N, Forrest G. Cryptococcosis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S192-S198
67. Proia L, Miller R. Endemic fungal infections in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S199-S207
68. Kubak BM, Huprikar SS. Emerging & rare fungal infections in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S208-S226
69. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S227-S233
70. Pappas PG, Silveira FP. Candida in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S173-S179
71. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12: 850-858
72. Hadley S, Huckabee C, Pappas PG, Daly J, Rabkin J, Kauffman CA, Merion RM, Karchmer AW. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 40-48
73. Person AK, Kontoyiannis DP, Alexander BD. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 2010; 24: 439-459
74. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003; 17: 113-134, viii
75. van Hal SJ, Marriott DJ, Chen SC, Nguyen Q, Sorrell TC, Ellis DH, Slavin MA. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis 2009; 11: 122-127
76. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535
77. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821
78. Fortún J, Martín-Dávila P, Montejo M, Muñoz P, Cisneros JM, Ramos A, Aragón C, Blanes M, San Juan R, Gavaldá J, Llinares P. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009; 87: 424-435
79. Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrión VS, Barrios C, Moreno E, Noriega AR, Paya CV. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174: 583-588
80. Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David Colby W. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003; 76: 977-983
81. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-737
82. Winkler M, Pratschke J, Schulz U, Zheng S, Zhang M, Li W, Lu M, Sgarabotto D, Sganga G, Kaskel P, Chandwani S, Ma L, Petrovic J, Shivaprakash M. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transpl Infect Dis 2010; 12: 230-237
83. Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion RM, Kauffman CA, Huckabee C, Cloud GA, Dismukes WE, Karchmer AW. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006; 6: 386-391
84. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39 Suppl 4: S200-S206
85. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S180-S191
86. Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK. A risk profile for invasive aspergillosis in liver transplant recipients. Infection 2009; 37: 313-319
87. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-1567
88. Singh N, Pruett TL, Houston S, Muñoz P, Cacciarelli TV, Wagener MM, Husain S. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 2006; 12: 1205-1209
89. Fortún J, Martín-Dávila P, Alvarez ME, Norman F, Sánchez-Sousa A, Gajate L, Bárcena R, Nuño SJ, Moreno S. Falsepositive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 2009; 87: 256-260
90. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT, Bacigalupo A. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillintazobactam. Clin Infect Dis 2004; 38: 913-916
91. Metan G, Agkus C, Buldu H, Koç AN. The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections. Infection 2010; 38: 217-221
92. Xavier MO, Pasqualotto AC, Aquino VR, Sukiennik TC, Severo LC. Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market. Braz J Infect Dis 2009; 13: 353-355